| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440431 | European Journal of Cancer | 2018 | 9 Pages |
Abstract
These results suggest that genomic alterations involving the cell cycle (TP53, CCND1, CDKN2A), as well as FGFR1 amplifications and tumour genomic alterations burden are prognostic biomarkers and might be therapeutic targets for patients with HNSCC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
C. Dubot, V. Bernard, M.P. Sablin, S. Vacher, W. Chemlali, A. Schnitzler, G. Pierron, K. Ait Rais, N. Bessoltane, E. Jeannot, J. Klijanienko, O. Mariani, T. Jouffroy, V. Calugaru, C. Hoffmann, M. Lesnik, N. Badois, F. Berger, I. Bieche,